In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement

Executive Summary

AstraZeneca agreed in late December to pay AtheroGenics a $50 million upfront fee and another $950 million in regulatory and commercial milestones for the biotech's VCAM-I inhibitor AGI-1067. Though many heralded the deal as a win-win for both companies, a closer analysis shows that AtheroGenics continues to shoulder the development costs--and risks--of the Phase III product.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel